Literature DB >> 25005007

Isolation and identification of Paenibacillus sp. FM-6, involved in the biotransformation of albendazole.

Lei Jin1, Xiaojun Zhang, Xiumei Sun, Hui Shi, Tiejun Li.   

Abstract

A strain, designated as FM-6, was isolated from fish. Based on the results of phenotypic, physiological characteristics, genotypic and phylogenetic analysis, strain FM-6 was finally identified as Paenibacillus sp. When albendazole was provided as the sole carbon source, strain FM-6 could grow and transform albendazole. About 82.7 % albendazole (50 mg/L) was transformed by strain FM-6 after 5 days incubation at 30 °C, 160 rpm. With HPLC-MS method, the transforming product of albendazole was researched. Based on the molecular weight and the retention time, product was identified as albendazole sulfoxide and the transforming pathway of albendazole by strain FM-6 was proposed finally. The optimum temperature and pH for the bacterium growth and albendazole transformation by strain FM-6 were both 30 °C and 7.0. Moreover, the optimum concentration of albendazole for the bacterium growth was 50 mg/L. Coupled with practical production, 50 mg/L was the optimum concentration of albendazole transformation for strain FM-6. This study highlights an important potential use of strain FM-6 for producing albendazole sulfoxide.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25005007     DOI: 10.1007/s11274-014-1698-9

Source DB:  PubMed          Journal:  World J Microbiol Biotechnol        ISSN: 0959-3993            Impact factor:   3.312


  15 in total

Review 1.  Application of microbial biotransformation for the new drug discovery using natural drugs as substrates.

Authors:  R K Venisetty; V Ciddi
Journal:  Curr Pharm Biotechnol       Date:  2003-06       Impact factor: 2.837

2.  Potential of thermophilic fungus Rhizomucor pusillus NRRL 28626 in biotransformation of antihelmintic drug albendazole.

Authors:  G Shyam Prasad; S Girisham; S M Reddy
Journal:  Appl Biochem Biotechnol       Date:  2011-08-12       Impact factor: 2.926

3.  New drugs of 1996.

Authors:  D A Hussar
Journal:  J Am Pharm Assoc (Wash)       Date:  1997 Mar-Apr

4.  Paenibacillus polymyxa PKB1 produces variants of polymyxin B-type antibiotics.

Authors:  Mohamed Shaheen; Jingru Li; Avena C Ross; John C Vederas; Susan E Jensen
Journal:  Chem Biol       Date:  2011-12-23

5.  Paenibacillus antarcticus sp. nov., a novel psychrotolerant organism from the Antarctic environment.

Authors:  Ma Jesús Montes; Elena Mercadé; Núria Bozal; Jesús Guinea
Journal:  Int J Syst Evol Microbiol       Date:  2004-09       Impact factor: 2.747

6.  Case report: Paenibacillus thiaminolyticus: a new cause of human infection, inducing bacteremia in a patient on hemodialysis.

Authors:  Jie Ouyang; Zhiheng Pei; Larry Lutwick; Sharvari Dalal; Liying Yang; Nicholas Cassai; Kuldip Sandhu; Bruce Hanna; Rosemary L Wieczorek; Martin Bluth; Matthew R Pincus
Journal:  Ann Clin Lab Sci       Date:  2008       Impact factor: 1.256

7.  Paenibacillus polymyxa rhizobacteria and their synthesized exoglycans in interaction with wheat roots: colonization and root hair deformation.

Authors:  Irina V Yegorenkova; Kristina V Tregubova; Vladimir V Ignatov
Journal:  Curr Microbiol       Date:  2013-01-12       Impact factor: 2.188

8.  Ecology and biotechnological potential of Paenibacillus polymyxa: a minireview.

Authors:  Sadhana Lal; Silvia Tabacchioni
Journal:  Indian J Microbiol       Date:  2009-04-21       Impact factor: 2.461

9.  Pharmacokinetics of albendazole in man.

Authors:  S E Marriner; D L Morris; B Dickson; J A Bogan
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

10.  Paenibacillus sp. strain JDR-2 and XynA1: a novel system for methylglucuronoxylan utilization.

Authors:  Franz J Stjohn; John D Rice; James F Preston
Journal:  Appl Environ Microbiol       Date:  2006-02       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.